Astellas Pharma Inc.
4503アステラス製薬株式会社
Latest half-year results
First half · fiscal year to 2026-03 · filed 2025-11-06For the first half of the fiscal year to 2026-03: Revenue ¥1.03 trillion (+10.1% YoY), Profit before tax ¥194.6 billion (+118.6% YoY), Net income ¥147.6 billion (+100.8% YoY).
| This period | Year on year | |
|---|---|---|
| Revenue | ¥1.0tn | +10.1% |
| Profit before tax | ¥194.6bn | +118.6% |
| Net profit to owners | ¥147.6bn | +100.8% |
From the securities report on EDINET, which states no forecast. History via /v1/companies/4503/earnings-releases.
Financials
IFRS · consolidated · fiscal year to 2026-03-31- Revenue
- ¥2.1tn
- Net income
- ¥291.5bn
- ROE
- 17.4%
- Equity ratio
- 51.3%
- Dividend / share
- ¥78
- Employees
- 14,099
| Fiscal year | Revenue | Net income | Total assets | Net assets | ROE | EPS | Operating CF |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | ¥2,139.2bn | ¥291.5bn | ¥3,567.0bn | ¥1,829.0bn | 17.4% | ¥162.77 | ¥560.2bn |
| 2025-03-31 | ¥1,912.3bn | ¥50.7bn | ¥3,339.5bn | ¥1,513.3bn | 3.3% | ¥28.35 | ¥194.5bn |
| 2024-03-31 | ¥1,603.7bn | ¥17.0bn | ¥3,569.6bn | ¥1,596.0bn | 1.1% | ¥9.51 | ¥172.5bn |
| 2023-03-31 | ¥1,518.6bn | ¥98.7bn | ¥2,456.5bn | ¥1,508.0bn | 6.7% | ¥54.24 | ¥327.8bn |
| 2022-03-31 | ¥1,296.2bn | ¥124.1bn | ¥2,332.4bn | ¥1,460.3bn | 8.7% | ¥67.08 | ¥257.4bn |
Indicators
Computed by us from filings · fiscal year to 2026-03-31| Metric | Value | Percentile among listed companies |
|---|---|---|
| ROE, % | 17.4 | 83.8 |
| Ordinary margin | 0.176 | 87.1 |
| Equity ratio, % | 51.3 | 43.1 |
| Revenue growth | 0.1187 | 74.1 |
| Net income growth | 4.7449 | 97.5 |
| Operating cash flow / assets | 0.157 | 90.9 |
Results wording balance: +1.00. Proprietary text method; it describes the wording only and does not interpret context.
Interest example: if all ¥566.0bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥2.8bn, 0.5% of operating cash flow. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.
Via /v1/companies/4503/indicators. Descriptive figures, not a rating and not investment advice.
From other filings
As the company states themOwnership changes
All companies →- 2026-01-20
BlackRock Japan Co., Ltd. raised holdings in Astellas Pharma Inc. (4503) to 9.54% from 8.51%.
- 2025-10-17
BlackRock Japan Co., Ltd. raised holdings in Astellas Pharma Inc. (4503) to 8.51% from 8.50%.
- 2025-09-19
Sumitomo Mitsui Trust Asset Management Co.,Ltd. reduced holdings in Astellas Pharma Inc. (4503) to 6.38% from 6.67%.
- 2025-09-18
BlackRock Japan Co., Ltd. reduced holdings in Astellas Pharma Inc. (4503) to 8.50% from 9.01%.
- 2025-05-20
BlackRock Japan Co., Ltd. raised holdings in Astellas Pharma Inc. (4503) to 9.01% from 8.80%.
- 2025-05-08
Mitsubishi UFJ Financial Group, Inc. disclosed a 5.03% stake in Astellas Pharma Inc. (4503), crossing the 5% reporting threshold.
- 2025-03-19
BlackRock Japan Co., Ltd. raised holdings in Astellas Pharma Inc. (4503) to 8.80% from 8.62%.
- 2024-12-05
BlackRock Japan Co., Ltd. raised holdings in Astellas Pharma Inc. (4503) to 8.62% from 7.50%.
- 2024-07-03
BlackRock Japan Co., Ltd. reduced holdings in Astellas Pharma Inc. (4503) to 7.50% from 8.52%.
- 2023-10-16
Mitsubishi UFJ Financial Group, Inc. cut holdings in Astellas Pharma Inc. (4503) to 4.81% from 5.19%, below the 5% threshold.
5% filings
Large shareholding reports on 4503| Filed | Filer | Stake | Change | Stated purpose |
|---|---|---|---|---|
| 2026-01-20 | BlackRock Japan Co., Ltd. | 9.54% | +1.03pt | pure investment |
| 2025-10-17 | BlackRock Japan Co., Ltd. | 8.51% | +0.01pt | pure investment |
| 2025-09-19 | Sumitomo Mitsui Trust Asset Management Co.,Ltd. | 6.38% | −0.29pt | — |
| 2025-09-18 | BlackRock Japan Co., Ltd. | 8.50% | −0.51pt | pure investment |
| 2025-05-20 | BlackRock Japan Co., Ltd. | 9.01% | +0.21pt | pure investment |
| 2025-05-08 | Mitsubishi UFJ Financial Group, Inc. | 5.03% | — | pure investment |
| 2025-03-19 | BlackRock Japan Co., Ltd. | 8.80% | +0.18pt | pure investment |
| 2024-12-05 | BlackRock Japan Co., Ltd. | 8.62% | +1.12pt | pure investment |
| 2024-07-03 | BlackRock Japan Co., Ltd. | 7.50% | −1.02pt | pure investment |
| 2023-10-16 | Mitsubishi UFJ Financial Group, Inc. | 4.81% | −0.38pt | pure investment |
Cross-shareholdings
From the annual report's status of shareholdings- Listed strategic holdings
- 2 issues
- Book value
- ¥1.8bn
- Sold in the year
- — — issues
- Bought in the year
- — — issues
- Mutual, both reports
- 0
- Held by listed cos.
- 12
| Holds | Book value | Shares vs. prior year | Mutual |
|---|---|---|---|
| Oncolys BioPharma Inc. 4588 | ¥1,569m | 0.0% | no |
| Kyntra Bio, Inc. | ¥214m | -96.0% | no |
Held by: Sumitomo Mitsui Financial Group, Inc. 8316, Iyogin Holdings,Inc. 5830, Takasago Thermal Engineering Co., Ltd. 1969, TSUMUGU Holdings, Inc. 3055, VITAL KSK HOLDINGS,INC. 3151, The Ogaki Kyoritsu Bank, Ltd. 8361, SODA NIKKA CO., LTD. 8158, KOBAYASHI PHARMACEUTICAL CO.,LTD. 4967, Nippon Fine Chemical Co., Ltd. 4362, Daito Pharmaceutical Co., Ltd. 4577, Sasatoku Printing Co., Ltd. 3958, ASAHI KOGYOSHA CO.,LTD. 1975
Purposes, all holdings and mutual flags via /v1/companies/4503/cross-holdings. Share changes include stock splits.
Major shareholders
As of fiscal year end 2026-03-31| Shareholder | Shares | Ratio |
|---|---|---|
| 日本マスタートラスト信託銀行株式会社 (信託口) | 343,200,000 | 18.96% |
| 株式会社日本カストディ銀行 (信託口) | 130,182,000 | 7.19% |
| 日本生命保険相互会社 | 51,588,000 | 2.85% |
| individual holder | 38,405,000 | 2.12% |
| ＪＰモルガン証券株式会社 | 30,057,000 | 1.66% |
| individual holder | 26,465,000 | 1.46% |
| ＳＭＢＣ日興証券株式会社 | 22,484,000 | 1.24% |
| 野村信託銀行株式会社 (投信口) | 22,218,000 | 1.22% |
| individual holder | 21,360,000 | 1.18% |
| 株式会社日本カストディ銀行 (信託口４) | 18,927,000 | 1.04% |
U.S. funds holding 4503
SEC Form N-PORT, reports to 2026-07-31368 U.S. funds held 233,630,692 shares worth $3.21bn.
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND VANGUARD STAR FUNDS | 26,399,861 | $362.6m | 0.056% | 2026-07-31 |
| VANGUARD DEVELOPED MARKETS INDEX FUND VANGUARD TAX-MANAGED FUNDS | 17,511,938 | $234.3m | 0.074% | 2026-06-30 |
| iShares Core MSCI EAFE ETF iShares Trust | 12,882,800 | $176.9m | 0.093% | 2026-07-31 |
| iShares MSCI Japan ETF iShares, Inc. | 7,371,450 | $105.0m | 0.493% | 2026-05-31 |
| Fidelity International Index Fund Fidelity Concord Street Trust | 6,809,771 | $97.0m | 0.116% | 2026-05-31 |
Up to 25 funds per stock via the API.
Get this as JSON
GET /v1/companies/4503
GET /v1/companies/4503/financials
GET /v1/companies/4503/details
GET /v1/companies/4503/segments
GET /v1/companies/4503/voting
GET /v1/companies/4503/tender-offers
GET /v1/companies/4503/indicators
GET /v1/companies/4503/earnings-releases
GET /v1/events?ticker=4503
GET /v1/companies/4503/trades
GET /v1/companies/4503/cross-holdings
GET /v1/companies/4503/brief